Anti-CD38 Antibody Interferon Construct for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using lenalidomide and pomalidomide face challenges with resistance and systemic toxicity, particularly in targeting CD38-expressing tumors, where interferon alpha-2b therapies can be effective but are limited by adverse effects on healthy cells.
Innovation Solution
A combination therapy involving an anti-CD38 antibody-attenuated interferon alpha-2b construct and lenalidomide or pomalidomide, where the construct is designed to enhance tumor targeting and reduce systemic toxicity by specifically delivering interferon to CD38-positive cells, thereby synergizing with lenalidomide or pomalidomide to inhibit tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon alpha-2b is administered to treat CD38-expressing tumors, then anti-tumor effects are achieved, but systemic toxicity increases due to impact on healthy cells
Solution Approach 1:
The patent employs an anti-CD38 antibody as an intermediary carrier to deliver interferon alpha-2b specifically to CD38-expressing tumor cells. The antibody binds to CD38 on the tumor cell surface, serving as a targeted delivery vehicle that concentrates the interferon at the tumor site while minimizing systemic circulation and exposure to healthy cells, thereby resolving the contradiction between anti-tumor efficacy and systemic toxicity
Solution Approach 2:
The invention creates local concentration of interferon alpha-2b at the tumor site through antibody-mediated targeting. By attaching interferon to an anti-CD38 antibody, the therapeutic agent is delivered specifically to CD38-positive tumor cells, creating high local concentration where it is needed while maintaining low systemic levels, thus achieving effective tumor treatment without widespread toxic effects on healthy tissues
2Reliability
If lenalidomide or pomalidomide is used to treat tumors, then tumor growth inhibition is achieved, but resistance develops over time
Solution Approach 1:
The patent combines lenalidomide or pomalidomide with the anti-CD38 antibody-attenuated interferon alpha-2b construct to create a multi-modal treatment approach. This combination targets tumors through multiple mechanisms: the immunomodulatory effects of lenalidomide/pomalidomide and the targeted cytotoxic effects of the antibody-interferon construct. By merging these different therapeutic mechanisms, the treatment overcomes resistance that would develop to either agent alone, as tumors cannot simultaneously adapt to multiple distinct modes of action
Solution Approach 2:
The invention creates a composite therapeutic regimen combining two distinct anti-tumor agents with different mechanisms of action. The lenalidomide/pomalidomide provides immunomodulation and direct anti-proliferative effects, while the antibody-interferon construct provides targeted cytotoxicity. This composite approach ensures that when resistance develops to one component, the other maintains therapeutic efficacy, preventing complete treatment failure
3Productivity
If interferon alpha-2b is administered at high doses to maximize anti-proliferative activity, then tumor cell apoptosis increases, but flu-like symptoms and systemic toxicity worsen
Solution Approach 1:
The anti-CD38 antibody serves as a targeted delivery intermediary that concentrates interferon alpha-2b at the tumor site, allowing effective anti-proliferative activity to be achieved at lower systemic doses. By mediating localized delivery, the antibody enables sufficient drug concentration at the target without requiring high systemic levels that would cause flu-like symptoms and toxicity in healthy tissues
Solution Approach 2:
The invention achieves high local concentration of interferon at the tumor site through antibody targeting, while maintaining low systemic circulation levels. This local quality approach allows the tumor cells to be exposed to high doses of interferon for maximum anti-proliferative effect, while healthy cells throughout the body are exposed to minimal levels, avoiding the flu-like symptoms and systemic toxicity associated with high-dose interferon administration
Data Source
AI summary
Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.